https://www.selleckchem.com/pr....oducts/larotrectinib
f the SPIBI shows positive results, it could be considered for clinical implementation for child-support, ethical and health-economic purposes. Regardless of the outcome, the trial will provide valuable information about extremely preterm children and their parents during infancy and toddlerhood after regional hospital care in Sweden. TRIAL REGISTRATION The study was registered in ClinicalTrials.gov in October 2018 (NCT03714633).BACKGROUND Optical quality and macular thickness changing optical quality is rarely reported after femt
Like
Comment
Share
